Drugs / peg-IFN alpha
peg-IFN alpha
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04640129 | Jan 2021 → Nov 2025 | fibrotic liver disease | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peg-IFN alpha | “INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen...” PMID 34697111 ↗ Oct 2021 |
| Known as | peg-IFN-α | “As another anti-HBV drug, pegylated-interferon-α (peg-IFN-α) has the immune regulation effect that NAs do not have” NCT04640129 ↗ |
| Known as | PEG-Interferon Alfa | “Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy” NCT04640129 ↗ |
| Known as | pegylated interferon alpha | “INTRODUCTION: Combination antiviral therapy of nucleos(t)ide analogue (NA) and pegylated interferon alpha (peg-IFN alpha) decrease hepatitis B virus (HBV) surface antigen...” PMID 34697111 ↗ Oct 2021 |
| Route | Subcutaneous | “Participants in the combination group will receive subcutaneous injections of peg-IFN alpha 180 µg per week for 48 weeks” PMID 34697111 ↗ Oct 2021 |